gnckКолопроктологияKoloproktologia2073-75562686-7303Russian Association of Coloproctology10.33878/2073-7556-2023-22-1-147-159gnck-1785Research ArticleОБЗОРЫ ЛИТЕРАТУРЫ И МЕТААНАЛИЗLITERATURE REVIEWS AND METAANALYSISЛекарственная терапия воспалительных заболеваний кишечника у беременных. Обзор актуальных данных по безопасности и эффективностиConservative treatment of inflammatory bowel diseases during pregnancy. Review of current safety and efficacy datahttps://orcid.org/0000-0002-5714-3462УспенскаяЮ. Б.UspenskayaYu. B.

Успенская Юлия Борисовна — доктор медицинских наук, ведущий гастроэнтеролог 

Столярный пер., д.3, г.Москва, 123022

Yulia B. Uspenskaya

Stolyarnyy lane, 3, Moscow, 123022

https://orcid.org/0000-0003-1697-4670НанаеваБ. А.NanaevaB. A.

Нанаева Бэлла Александровна — кандидат медицинских наук, заведующая гастроэнтерологическим отделением 

ул. Саляма Адиля, д.2, г.Москва, 123423

Bella A. Nanaeva

Salyama Adilya str., 2, Moscow, 123423

nanaeva_ba@gnck.ruhttps://orcid.org/0000-0002-3146-0400ОлейникВ. А.OleynikV. A.

Олейник Виктория Андреевна — младший научный сотрудник отдела по изучению воспалительных и функциональных заболеваний кишечника 

ул. Саляма Адиля, д.2, г.Москва, 123423

Victoria A. Oleynik

Salyama Adilya str., 2, Moscow, 123423

ООО «Медсанчасть №14» (клиника РассветРоссияLLC «Medical Unit № 14» (Сlinic «Rassvet»)Russian FederationФГБУ «НМИЦ колопроктологии имени А.Н. Рыжих» Минздрава РоссииRussian FederationRyzhikh National Medical Research Center of ColoproctologyRussian Federation202321032023221147159Copyright © Успенская Ю.Б., Нанаева Б.А., Олейник В.А., 20232023Успенская Ю.Б., Нанаева Б.А., Олейник В.А.Uspenskaya Y.B., Nanaeva B.A., Oleynik V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ruproctology.com/jour/article/view/1785

Пик заболеваемости язвенным колитом (ЯК) и болезнью Крона (БК) во всем мире приходится на детородный возраст. Высокая активность воспалительных заболеваний кишечника (ВЗК) во время беременности является фактором риска развития акушерских осложнений, в связи с чем необходим контроль над течением заболеваний. Из-за недостатка информации о безопасности лекарственная терапия часто необоснованно отменяется во время беременности. В публикации приводятся современные данные о безопасности у беременных базовой и таргетной терапии ЯК и БК.

The incidence of ulcerative colitis (UC) and Crohn’s disease (CD) worldwide falls on the childbearing age. High activity of inflammatory bowel diseases (IBD) during pregnancy is a risk factor for the development of obstetric complications, and therefore it is necessary to control the course of diseases. Due to the lack of safety information, drug therapy is often unreasonably canceled during pregnancy. The publication provides up-to-date on the safety of basic and targeted therapy of UC and CD in pregnant.

язвенный колитболезнь Кронавоспалительные заболевания кишечникабеременностьulcerative colitisCrohn’s diseaseinflammatory bowel diseasespregnancyReferencesKaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56–66. Epub 2020 Oct 8. PMID: 33033392; PMCID: PMC7542092. doi: 10.1038/s41575-020-00360-xKaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56–66. Epub 2020 Oct 8. PMID: 33033392; PMCID: PMC7542092. doi: 10.1038/s41575-020-00360-xMolodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46–54. e42; quiz e30. Epub 2011 Oct 14. PMID: 22001864. doi: 10.1053/j.gastro.2011.10.001Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46–54. e42; quiz e30. Epub 2011 Oct 14. PMID: 22001864. doi: 10.1053/j.gastro.2011.10.001Pedersen N, Bortoli A, Duricova D, et al. European Crohn-Colitis Organisation-ECCO-Study Group of Epidemiology Committee-EpiCom. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013 Sep;38(5):501–12. Epub 2013 Jul 15. PMID: 23855425. doi: 10.1111/apt.12412Pedersen N, Bortoli A, Duricova D, et al. European Crohn-Colitis Organisation-ECCO-Study Group of Epidemiology Committee-EpiCom. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013 Sep;38(5):501–12. Epub 2013 Jul 15. PMID: 23855425. doi: 10.1111/apt.12412Dickson I. Pregnancy safe and beneficial for women with IBD. Nat Rev Gastroenterol Hepatol. 2019;16(8):454.Dickson I. Pregnancy safe and beneficial for women with IBD. Nat Rev Gastroenterol Hepatol. 2019;16(8):454.Eisfeld H, Glimm AM, Burmester GR, et al. Pregnancy outcome in women with different rheumatic diseases: a retrospective analysis. Scand J Rheumatol. 2021 Jul;50(4):299–306. Epub 2021 Feb 24. PMID: 33622159. doi: 10.1080/03009742.2020.1849788Eisfeld H, Glimm AM, Burmester GR, et al. Pregnancy outcome in women with different rheumatic diseases: a retrospective analysis. Scand J Rheumatol. 2021 Jul;50(4):299–306. Epub 2021 Feb 24. PMID: 33622159. doi: 10.1080/03009742.2020.1849788Molnár T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol. 2010;45(11), 1302-1306.Molnár T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol. 2010;45(11), 1302-1306.Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013 Sep;132(3):e796-809. Epub 2013 Aug 26. PMID: 23979084. doi: 10.1542/peds.2013-1985Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013 Sep;132(3):e796-809. Epub 2013 Aug 26. PMID: 23979084. doi: 10.1542/peds.2013-1985McConnell RA, Mahadevan U. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications. Gastroenterol Clin North Am. 2016 Jun;45(2):285– 301. PMID: 27261899. doi: 10.1016/j.gtc.2016.02.006McConnell RA, Mahadevan U. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications. Gastroenterol Clin North Am. 2016 Jun;45(2):285– 301. PMID: 27261899. doi: 10.1016/j.gtc.2016.02.006Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019 Apr;156(5):1508–1524. Epub 2019 Jan 16. PMID: 30658060. doi: 10.1053/j.gastro.2018.12.022Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019 Apr;156(5):1508–1524. Epub 2019 Jan 16. PMID: 30658060. doi: 10.1053/j.gastro.2018.12.022Nielsen OH, Gubatan JM, Juhl CB, et al. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;20:74–87.Nielsen OH, Gubatan JM, Juhl CB, et al. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;20:74–87.Lee HH, Bae JM, Lee BI, et al. Pregnancy outcomes in women with inflammatory bowel disease: a 10-year nationwide population-based cohort study. Aliment Pharmacol Ther. 2020 May;51(9):861–869. Epub 2020 Apr 7. PMID: 32266739. doi: 10.1111/apt.15654Lee HH, Bae JM, Lee BI, et al. Pregnancy outcomes in women with inflammatory bowel disease: a 10-year nationwide population-based cohort study. Aliment Pharmacol Ther. 2020 May;51(9):861–869. Epub 2020 Apr 7. PMID: 32266739. doi: 10.1111/apt.15654Rottenstreich A, Fridman Lev S, Rotem R, et al. Disease flare at prior pregnancy and disease activity at conception are important determinants of disease relapse at subsequent pregnancy in women with inflammatory bowel diseases. Arch Gynecol Obstet. 2020 Jun;301(6):1449–1454. Epub 2020 May 6. PMID: 32377786. doi: 10.1007/s00404-020-05557-8Rottenstreich A, Fridman Lev S, Rotem R, et al. Disease flare at prior pregnancy and disease activity at conception are important determinants of disease relapse at subsequent pregnancy in women with inflammatory bowel diseases. Arch Gynecol Obstet. 2020 Jun;301(6):1449–1454. Epub 2020 May 6. PMID: 32377786. doi: 10.1007/s00404-020-05557-8Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf. 2021 Mar;20(3):275–292. Epub 2021 Feb 5. PMID: 33412078. doi: 10.1080/14740338.2021.1873948Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf. 2021 Mar;20(3):275–292. Epub 2021 Feb 5. PMID: 33412078. doi: 10.1080/14740338.2021.1873948Walldorf J, Pijan E, Greinert R, et al. Family planning with inflammatory bowel disease: the challenge of childlessness and parent concerns. Z Gastroenterol. 2021 Aug;59(8):841–850. Epub 2021 Mar 18. PMID: 33735917. doi: 10.1055/a-1404-3610Walldorf J, Pijan E, Greinert R, et al. Family planning with inflammatory bowel disease: the challenge of childlessness and parent concerns. Z Gastroenterol. 2021 Aug;59(8):841–850. Epub 2021 Mar 18. PMID: 33735917. doi: 10.1055/a-1404-3610Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25:271–275.Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25:271–275.Hernandez-Diaz S, Mitchell AA, Kelley KE, et al. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect. 2009;117:185–189.Hernandez-Diaz S, Mitchell AA, Kelley KE, et al. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect. 2009;117:185–189.Jurewicz J, Hanke W. Exposure to phthalates: reproductive outcome and children health. A review of epidemiological studies. Int J Occup Med Environ Health. 2011;24:115–141.Jurewicz J, Hanke W. Exposure to phthalates: reproductive outcome and children health. A review of epidemiological studies. Int J Occup Med Environ Health. 2011;24:115–141.Singh A, Martin CF, Kane SV, et al. Is asacol use associated with congenital anomalies? Results from a nationwide prospective pregnancy registry: su1030. Gastroenterology. 2013;144. doi: 10.1053/j.gastro.2012.10.005Singh A, Martin CF, Kane SV, et al. Is asacol use associated with congenital anomalies? Results from a nationwide prospective pregnancy registry: su1030. Gastroenterology. 2013;144. doi: 10.1053/j.gastro.2012.10.005Baggott J, Morgan S, Ha T, et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J. 1992;282:197–202.Baggott J, Morgan S, Ha T, et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J. 1992;282:197–202.Shannahan SE, Erlich JM, Peppercorn MA. Insights into the treatment of inflammatory bowel disease in pregnancy. Therap Adv Gastroenterol. 2019;12:175628481985223.Shannahan SE, Erlich JM, Peppercorn MA. Insights into the treatment of inflammatory bowel disease in pregnancy. Therap Adv Gastroenterol. 2019;12:175628481985223.Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183:796–804.Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183:796–804.Leung YP, Kaplan GG, Coward S, et al. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohns Colitis. 2015;9:223–230.Leung YP, Kaplan GG, Coward S, et al. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohns Colitis. 2015;9:223–230.Lin K, Martin CF, Dassopoulos T, et al. Pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO registry. Gastroenterology. 2014;146:S1.Lin K, Martin CF, Dassopoulos T, et al. Pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO registry. Gastroenterology. 2014;146:S1.Truta B, Althumairi A, Canner J, et al. Potential risks of immunosuppressant drugs to the pregnant patient. Am J Gastroenterol. 2015;110:S966.Truta B, Althumairi A, Canner J, et al. Potential risks of immunosuppressant drugs to the pregnant patient. Am J Gastroenterol. 2015;110:S966.Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev. 2005;57:303–316.Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev. 2005;57:303–316.Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis. 2009 Jan;15(1):25–8. PMID: 18680195. doi: 10.1002/ibd.20640Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis. 2009 Jan;15(1):25–8. PMID: 18680195. doi: 10.1002/ibd.20640Rahim MN, Ran S, Shah S, et al. Safety and Efficacy of Budesonide During Pregnancy in Women With Autoimmune Hepatitis. Hepatology. 2021 Jun;73(6):2601–2606. Epub 2021 May 24. PMID: 33188708. doi: 10.1002/hep.31634Rahim MN, Ran S, Shah S, et al. Safety and Efficacy of Budesonide During Pregnancy in Women With Autoimmune Hepatitis. Hepatology. 2021 Jun;73(6):2601–2606. Epub 2021 May 24. PMID: 33188708. doi: 10.1002/hep.31634van der Woude CJ, Ardizzone S, Bengtson MB, et al. ECCO: The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. 2018. https://gastropregnancy.com/spetsialistam/2-j-konsensus-ecco-po-reproduktivnomu-zdorovyu-zhenshhin-s-vzkvan der Woude CJ, Ardizzone S, Bengtson MB, et al. ECCO: The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. 2018. https://gastropregnancy.com/spetsialistam/2-j-konsensus-ecco-po-reproduktivnomu-zdorovyu-zhenshhin-s-vzkNguyen GC, Seow CH, Maxwell C, et al. IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016 Mar;150(3):734– 757.e1. Epub 2015 Dec 11. PMID: 26688268. doi: 10.1053/j.gastro.2015.12.003Nguyen GC, Seow CH, Maxwell C, et al. IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016 Mar;150(3):734– 757.e1. Epub 2015 Dec 11. PMID: 26688268. doi: 10.1053/j.gastro.2015.12.003Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85:647– 654.Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85:647– 654.Hutson JR, Matlow JN, Moretti ME, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2013;33(1):1–8. doi: 10.3109/01443615.2012.716106Hutson JR, Matlow JN, Moretti ME, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2013;33(1):1–8. doi: 10.3109/01443615.2012.716106de Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006;101(6):1390–1392. doi: 10.1111/j.1572-0241.2006.00538.xde Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006;101(6):1390–1392. doi: 10.1111/j.1572-0241.2006.00538.xJharap B, de Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63(3):451–457. doi: 10.1136/gutjnl-2012-303615Jharap B, de Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63(3):451–457. doi: 10.1136/gutjnl-2012-303615Selinger CP, Nelson-Piercy C, Fraser A, et al. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol. 2020 May 19;12(3):214–224. PMID: 33912333; PMCID: PMC8040511. doi: 10.1136/flgastro-2019-101371Selinger CP, Nelson-Piercy C, Fraser A, et al. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol. 2020 May 19;12(3):214–224. PMID: 33912333; PMCID: PMC8040511. doi: 10.1136/flgastro-2019-101371Akbari M, Shah S, Velayos FS, et al. Systematic review and metaanalysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22. doi: 10.1002/ibd.22948Akbari M, Shah S, Velayos FS, et al. Systematic review and metaanalysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22. doi: 10.1002/ibd.22948Kanis SL, de Lima-Karagiannis A, de Boer NKH, et al. Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study. Clin Gastroenterol Hepatol. 2017;15(8):1232–1241. e1. doi: 10.1016/j.cgh.2017.02.041Kanis SL, de Lima-Karagiannis A, de Boer NKH, et al. Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study. Clin Gastroenterol Hepatol. 2017;15(8):1232–1241. e1. doi: 10.1016/j.cgh.2017.02.041Zhang Y, Li D, Guo H, et al. Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis. Curr Pharm Des. 2021;27(19):2317–2324. PMID: 32938343. doi: 10.2174/1381612826666200916144249Zhang Y, Li D, Guo H, et al. Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis. Curr Pharm Des. 2021;27(19):2317–2324. PMID: 32938343. doi: 10.2174/1381612826666200916144249Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152(2):451–462.e. doi: 10.1053/j.gastro.2016.10.013Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152(2):451–462.e. doi: 10.1053/j.gastro.2016.10.013Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810. doi: 10.1136/annrheumdis-2015-208840Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810. doi: 10.1136/annrheumdis-2015-208840Анкилозирующий спондилит: клинические рекомендации. 2018. http://cr.rosminzdrav.ru/#!/schema/175 (Дата доступа: 3.08.2022).Ankylosing spondylitis: clinical guidelines. 2018. http://cr.rosminzdrav.ru/#!/schema/175 (Date: 3.08.2022). (in Russ.).Клинические рекомендации. Ревматоидный артрит. Ассоциация ревматологов России. 2018 г. http://cr.rosminzdrav.ru/#!/recomend/173Clinical recommendations. Rheumatoid arthritis. Association of Rheumatologists of Russia. 2018 г. http://cr.rosminzdrav.ru/#!/recomend/173 (in Russ.).Broms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091–1098.Broms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091–1098.Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1- s106. Epub 2019 Sep 27. Erratum in: Gut. 2021 Apr;70(4):1. PMID: 31562236; PMCID: PMC6872448. doi: 10.1136/gutjnl-2019-318484Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1- s106. Epub 2019 Sep 27. Erratum in: Gut. 2021 Apr;70(4):1. PMID: 31562236; PMCID: PMC6872448. doi: 10.1136/gutjnl-2019-318484Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1d87cc12-bf19-4072-82fe-88ea48f6eb4dState Register of Medicines. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1d87cc12-bf19-4072-82fe-88ea48f6eb4d (in Russ.).Adachi J, DuPont H. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Expert Rev Anti Infect Ther. 2006;42:541–547.Adachi J, DuPont H. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Expert Rev Anti Infect Ther. 2006;42:541–547.Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51(Suppl 1):36–66.Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51(Suppl 1):36–66.Simister N. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365–9.Simister N. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365–9.Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:quiz e24:286–92.Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:quiz e24:286–92.Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016;151:110–9.Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016;151:110–9.Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228–233. Epub 2017 Oct 13. PMID: 29030361; PMCID: PMC5867410. doi: 10.1136/annrheumdis-2017-212196Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228–233. Epub 2017 Oct 13. PMID: 29030361; PMCID: PMC5867410. doi: 10.1136/annrheumdis-2017-212196Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769–2778. Epub 2017 Oct 16. Erratum in: Lancet. 2020 Oct 3;396(10256):e56. PMID: 29050646. doi: 10.1016/S0140-6736(17)32448-0Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769–2778. Epub 2017 Oct 16. Erratum in: Lancet. 2020 Oct 3;396(10256):e56. PMID: 29050646. doi: 10.1016/S0140-6736(17)32448-0Mahadevan U, Martin C, Kane SV, et al. Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO Registry. Gastroenterology. 2016;150:S91– S92.Mahadevan U, Martin C, Kane SV, et al. Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO Registry. Gastroenterology. 2016;150:S91– S92.Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterol. 2021;160(4):1131–9.Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterol. 2021;160(4):1131–9.Chaparro M, Verreth A, Lobaton T, et al. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. Am J Gastroenterol. 2018 Mar;113(3):396–403. Epub 2018 Feb 20. PMID: 29460920. doi: 10.1038/ajg.2017.501Chaparro M, Verreth A, Lobaton T, et al. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. Am J Gastroenterol. 2018 Mar;113(3):396–403. Epub 2018 Feb 20. PMID: 29460920. doi: 10.1038/ajg.2017.501Scott R, Parker H, Mccartney S, et al. Outcomes following biosimilar TNF inhibitor use for inflammatory-mediated immune disorders in pregnancy. Obstet Med. 2022 Jun;15(2):104– 107. Epub 2021 Sep 2. PMID: 35845229; PMCID: PMC9277732. doi: 10.1177/1753495X211028779Scott R, Parker H, Mccartney S, et al. Outcomes following biosimilar TNF inhibitor use for inflammatory-mediated immune disorders in pregnancy. Obstet Med. 2022 Jun;15(2):104– 107. Epub 2021 Sep 2. PMID: 35845229; PMCID: PMC9277732. doi: 10.1177/1753495X211028779Kanis SL, Modderman S, Escher JC, et al. Initiative on Crohns and Colitis (ICC). Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut. 2021 Jul;70(7):1266–1274. Epub 2020 Oct 12. PMID: 33046558; PMCID: PMC8223671. doi: 10.1136/gutjnl-2019-319129Kanis SL, Modderman S, Escher JC, et al. Initiative on Crohns and Colitis (ICC). Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut. 2021 Jul;70(7):1266–1274. Epub 2020 Oct 12. PMID: 33046558; PMCID: PMC8223671. doi: 10.1136/gutjnl-2019-319129Luu M, Benzenine E, Doret M, et al. Continuous anti-TNF alpha use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol. 2018;113(11):1669–77.Luu M, Benzenine E, Doret M, et al. Continuous anti-TNF alpha use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol. 2018;113(11):1669–77.Truta B, Canner JK, Fang SH, et al. Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease. Gastro Hep Advances. 2022;1:785–791. doi: 10.1016/j.gastha.2022.04.009Truta B, Canner JK, Fang SH, et al. Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease. Gastro Hep Advances. 2022;1:785–791. doi: 10.1016/j.gastha.2022.04.009Truta B, Leeds IL, Canner JK, et al. Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 Jun 18;26(7):1110–1117. PMID: 31670762. doi: 10.1093/ibd/izz250Truta B, Leeds IL, Canner JK, et al. Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 Jun 18;26(7):1110–1117. PMID: 31670762. doi: 10.1093/ibd/izz250Lau A, Clark M, Harrison DD, et al. Pregnancy outcomes in women exposed to the tumor necrosis factor inhibitor, Golimumab. Ann Rheum Dis. 2014;73(Suppl2):232.2–3.Lau A, Clark M, Harrison DD, et al. Pregnancy outcomes in women exposed to the tumor necrosis factor inhibitor, Golimumab. Ann Rheum Dis. 2014;73(Suppl2):232.2–3.Wieringa JW, Driessen GJ, Van Der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterol Hepatol. 2018;12(8):811–8.Wieringa JW, Driessen GJ, Van Der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterol Hepatol. 2018;12(8):811–8.Kolar M, Bortlik M, Duricova D, et al. Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab. Gastroenterol Hepatol. 2018;72:20–26.Kolar M, Bortlik M, Duricova D, et al. Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab. Gastroenterol Hepatol. 2018;72:20–26.Komaki F, Komaki Y, Micic D, et al. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-a use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmunity. 2017;76:38–52.Komaki F, Komaki Y, Micic D, et al. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-a use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmunity. 2017;76:38–52.Shihab Z, Yeomans ND and de Cruz P. Anti-tumour necrosis factor a therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. J Crohns Colitis. 2016;10:979–988.Shihab Z, Yeomans ND and de Cruz P. Anti-tumour necrosis factor a therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. J Crohns Colitis. 2016;10:979–988.Julsgaard M, Kjeldsen J, Brock B, et al. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48:386–8.Julsgaard M, Kjeldsen J, Brock B, et al. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48:386–8.Mahadevan U, Vermeire S, Lasch K, et al. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors’ reply. Aliment Pharmacol Ther. 2018;48:388–9.Mahadevan U, Vermeire S, Lasch K, et al. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors’ reply. Aliment Pharmacol Ther. 2018;48:388–9.Mitrova K, Pipek B, Bortlik M, et al. Czech IBD Working Group. Safety of ustekinumab and vedolizumab during pregnancy — pregnancy, neonatal and infant outcome: a prospective multicenter study. J Crohns Colitis. 2022 Jun 16:jjac086. Epub ahead of print. PMID: 35708729. doi: 10.1093/ecco-jcc/jjac086Mitrova K, Pipek B, Bortlik M, et al. Czech IBD Working Group. Safety of ustekinumab and vedolizumab during pregnancy — pregnancy, neonatal and infant outcome: a prospective multicenter study. J Crohns Colitis. 2022 Jun 16:jjac086. Epub ahead of print. PMID: 35708729. doi: 10.1093/ecco-jcc/jjac086Crawford D, Friedman M. Evaluation of the Developmental Toxicity of Vedolizumab, an α4 β7 Receptor Antagonist, in Rabbit and Nonhuman Primate. Int J Toxicol. 2019;38:395–404.Crawford D, Friedman M. Evaluation of the Developmental Toxicity of Vedolizumab, an α4 β7 Receptor Antagonist, in Rabbit and Nonhuman Primate. Int J Toxicol. 2019;38:395–404.Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51(1):129–138. doi: 10.1111/apt.15539Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51(1):129–138. doi: 10.1111/apt.15539Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, et al. Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study. Am J Gastroenterol. 2019;114(7):1172–1175. doi: 10.14309/ajg.0000000000000186Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, et al. Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study. Am J Gastroenterol. 2019;114(7):1172–1175. doi: 10.14309/ajg.0000000000000186Nielsen OH, Gubatan JM, Juhl CB, et al. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):74–87.e3. Epub 2020 Sep 12. PMID: 32931960. doi: 10.1016/j.cgh.2020.09.021Nielsen OH, Gubatan JM, Juhl CB, et al. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):74–87.e3. Epub 2020 Sep 12. PMID: 32931960. doi: 10.1016/j.cgh.2020.09.021Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human antiIL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89(5):351–63.Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human antiIL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89(5):351–63.Mugheddu C, Atzori L, Lappi A, et al. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient. Dermatol Ther. 2019;32(3):e12895. 32.Mugheddu C, Atzori L, Lappi A, et al. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient. Dermatol Ther. 2019;32(3):e12895. 32.Wils P, Seksik P, Stefanescu C, et al. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther. 2021;53(4):460– 70.Wils P, Seksik P, Stefanescu C, et al. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther. 2021;53(4):460– 70.de Lima A, Zelinkova Z, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261–8.de Lima A, Zelinkova Z, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261–8.Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40(4):363–73.Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40(4):363–73.Mahadevan U, Naureckas S, Tikhonov I, et al. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer’s global safety database. Aliment Pharmacol Ther. 2022 Aug;56(3):477–490. Epub 2022 May 12. PMID: 35560249. doi: 10.1111/apt.16960Mahadevan U, Naureckas S, Tikhonov I, et al. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer’s global safety database. Aliment Pharmacol Ther. 2022 Aug;56(3):477–490. Epub 2022 May 12. PMID: 35560249. doi: 10.1111/apt.16960Armuzzi A, Bortoli A, Castiglione F, et al. Italian Group for the Study of Inflammatory Bowel Disease Working Group. Female reproductive health and inflammatory bowel disease: A practice-based review. Dig Liver Dis. 2022 Jan;54(1):19–29. Epub 2021 Jun 11. PMID: 34120858. doi: 10.1016/j.dld.2021.05.020Armuzzi A, Bortoli A, Castiglione F, et al. Italian Group for the Study of Inflammatory Bowel Disease Working Group. Female reproductive health and inflammatory bowel disease: A practice-based review. Dig Liver Dis. 2022 Jan;54(1):19–29. Epub 2021 Jun 11. PMID: 34120858. doi: 10.1016/j.dld.2021.05.020Picardo S, Seow CH. A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: biologic and oral small molecule therapy. Drugs. 2019;79:1053–63.Picardo S, Seow CH. A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: biologic and oral small molecule therapy. Drugs. 2019;79:1053–63.Clowse ME, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39:755–62.Clowse ME, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39:755–62.Yu A, Friedman S, Ananthakrishnan AN. Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 Nov 19;26(12):1926–1932. PMID: 31895410; PMCID: PMC7676422. doi: 10.1093/ibd/izz313Yu A, Friedman S, Ananthakrishnan AN. Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 Nov 19;26(12):1926–1932. PMID: 31895410; PMCID: PMC7676422. doi: 10.1093/ibd/izz313Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005 Jan;100(1):102–5. PMID: 15654788. doi: 10.1111/j.1572-0241.2005.40785.xKane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005 Jan;100(1):102–5. PMID: 15654788. doi: 10.1111/j.1572-0241.2005.40785.xMañosa M, Navarro-Llavat M, Marín L, et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol. 2013 Apr;48(4):427–32. Epub 2013 Mar 11. PMID: 23477328. doi: 10.3109/00365521.2013.772229Mañosa M, Navarro-Llavat M, Marín L, et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol. 2013 Apr;48(4):427–32. Epub 2013 Mar 11. PMID: 23477328. doi: 10.3109/00365521.2013.772229Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013;7:e206-13.Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013;7:e206-13.Barclay AR, Russell RK, Wilson ML, et al. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr. 2009 Sep;155(3):421–6. Epub 2009 May 22. PMID: 19464699. doi: 10.1016/j.jpeds.2009.03.017Barclay AR, Russell RK, Wilson ML, et al. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr. 2009 Sep;155(3):421–6. Epub 2009 May 22. PMID: 19464699. doi: 10.1016/j.jpeds.2009.03.017Datta P, Rewers-Felkins K, Kallem RR, et al. Determination of Mesalamine levels in Human Milk as a Function of Dose. Breastfeed Med. 2019 Mar;14(2):98–101. Epub 2018 Nov 15. PMID: 30431332. doi: 10.1089/bfm.2018.0111Datta P, Rewers-Felkins K, Kallem RR, et al. Determination of Mesalamine levels in Human Milk as a Function of Dose. Breastfeed Med. 2019 Mar;14(2):98–101. Epub 2018 Nov 15. PMID: 30431332. doi: 10.1089/bfm.2018.0111Jarnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol. 1979;14:869–871.Jarnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol. 1979;14:869–871.Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhoea — a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastr Nutr. 1986;5:316–317.Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhoea — a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastr Nutr. 1986;5:316–317.Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008 Nov 15;28(10):1209–13. Epub 2008 Aug 30. PMID: 18761704. doi: 10.1111/j.1365-2036.2008.03843.xChristensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008 Nov 15;28(10):1209–13. Epub 2008 Aug 30. PMID: 18761704. doi: 10.1111/j.1365-2036.2008.03843.xAngelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011 Apr;5(2):95–100. Epub 2010 Dec 9. PMID: 21453877. doi: 10.1016/j.crohns.2010.10.005Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011 Apr;5(2):95–100. Epub 2010 Dec 9. PMID: 21453877. doi: 10.1016/j.crohns.2010.10.005Ost L, Wettrell G, Björkhem I, et al. Prednisolone excretion in human milk. J Pediatr. 1985 Jun;106(6):1008–11. PMID: 3998938. doi: 10.1016/s0022-3476(85)80259-6Ost L, Wettrell G, Björkhem I, et al. Prednisolone excretion in human milk. J Pediatr. 1985 Jun;106(6):1008–11. PMID: 3998938. doi: 10.1016/s0022-3476(85)80259-6Greenberger PA, Odeh YK, Frederiksen MC, et al. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther. 1993 Mar;53(3):324–8. PMID: 8453851. doi: 10.1038/clpt.1993.28Greenberger PA, Odeh YK, Frederiksen MC, et al. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther. 1993 Mar;53(3):324–8. PMID: 8453851. doi: 10.1038/clpt.1993.28American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776–89. PMID: 11533352. doi: 10.1542/peds.108.3.776American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776–89. PMID: 11533352. doi: 10.1542/peds.108.3.776Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8(5):475– 6.Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8(5):475– 6.Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5(6):555–8.Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5(6):555–8.Fritzsche J, Pilch A, Mury D, et al. Infiximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012;46(8):718–9.Fritzsche J, Pilch A, Mury D, et al. Infiximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012;46(8):718–9.Matro R, Martin CF, Wolf D, et al. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018 Sep;155(3):696–704. Epub 2018 May 30. PMID: 29857090. doi: 10.1053/j.gastro.2018.05.040Matro R, Martin CF, Wolf D, et al. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018 Sep;155(3):696–704. Epub 2018 May 30. PMID: 29857090. doi: 10.1053/j.gastro.2018.05.040Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890–6.Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890–6.Puchner A, Gröchenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr. 2019 Jan;131(1-2):29–44. Epub 2019 Jan 14. PMID: 30643992; PMCID: PMC6342891. doi: 10.1007/s00508-019-1448-yPuchner A, Gröchenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr. 2019 Jan;131(1-2):29–44. Epub 2019 Jan 14. PMID: 30643992; PMCID: PMC6342891. doi: 10.1007/s00508-019-1448-ySun W, Fennimore B, Beaulieu DB, et al. Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease. Clin Pharmacokinet. 2021 Jun;60(6):811–818. Epub 2021 Feb 5. PMID: 33544318; PMCID: PMC8195772. doi: 10.1007/s40262-021-00985-4Sun W, Fennimore B, Beaulieu DB, et al. Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease. Clin Pharmacokinet. 2021 Jun;60(6):811–818. Epub 2021 Feb 5. PMID: 33544318; PMCID: PMC8195772. doi: 10.1007/s40262-021-00985-4Julsgaard M, Kjeldsen J, Bibby BM, et al. Vedolizumab concentrations in the breast milk of nursing mothers with infammatory bowel disease. Gastroenterology. 2018;154(3):752–4.e1.Julsgaard M, Kjeldsen J, Bibby BM, et al. Vedolizumab concentrations in the breast milk of nursing mothers with infammatory bowel disease. Gastroenterology. 2018;154(3):752–4.e1.Lahat A, Shitrit AB, Naftali T, et al. Vedolizumab levels in breast milk of nursing mothers with infammatory bowel disease. J Crohns Colitis. 2018;12.Lahat A, Shitrit AB, Naftali T, et al. Vedolizumab levels in breast milk of nursing mothers with infammatory bowel disease. J Crohns Colitis. 2018;12.Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16:99–105.Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16:99–105.de Lima A, Kanis SL, Escher JC, et al. Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero. J Crohns Colitis. 2018;12:948–53.de Lima A, Kanis SL, Escher JC, et al. Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero. J Crohns Colitis. 2018;12:948–53.Bendaoud S, Nahon S, Gornet J-M, et al. Live-vaccines and lactation in newborn exposed in utero to anti-TNF: A multi-centre French experience in inflammatory bowel disease. J Crohn’s Colitis. 2018;12(Suppl 1):S527.Bendaoud S, Nahon S, Gornet J-M, et al. Live-vaccines and lactation in newborn exposed in utero to anti-TNF: A multi-centre French experience in inflammatory bowel disease. J Crohn’s Colitis. 2018;12(Suppl 1):S527.

The authors declare that there are no conflicts of interest present.